Weekly Spotlight - 27.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

New Hope for Primary Biliary Cholangitis Patients

Recent approvals in the US and UK offer hope for primary biliary cholangitis(PBC) patients. Elafibranor and seladelpar, new oral drugs, reduce bile acid synthesis, improving liver function. Obeticholic acid remains available in Europe. Fibrates are used off-label for those intolerant to ursodiol. 

Ursodeoxycholic Acid Reduces Severe COVID-19 Risk in Liver Patients

Ursodeoxycholic acid (UDCA), a treatment for liver diseases, may reduce severe COVID-19 outcomes. A study using UK health records found UDCA users had a 21% lower risk of COVID-19 hospitalisation or death. This suggests UDCA could be a preventative measure, warranting further clinical trials. 

Iqirvo Shows Promise in Treating Primary Biliary Cholangitis

Ipsen's Iqirvo shows promising results for primary biliary cholangitis, a rare liver disease. Over three years, 85 patients had a biochemical response, and 39 achieved ALP normalisation. The drug, taken daily, reduces bile toxicity. Approved by health authorities, it offers hope for those affected, especially women. 

Living with PBC: Understanding Vitamin Deficiencies and Care

Primary biliary cholangitis (PBC) is an autoimmune liver disease causing vitamin deficiencies, notably vitamin D, affecting bone health. Alcohol doesn't cause PBC, but excessive use can worsen liver damage. Treatment includes medications like UDCA and lifestyle changes. Early diagnosis and management are crucial for better outcomes.